Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 7, 2013, Pages

  Tam, Julian ^a   Nash, Edward F ^b   Ratjen, Felix ^c   Tullis, Elizabeth ^d   Stephenson, Anne ^d  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMBROXOL; CARBOCISTEINE; GLUTATHIONE; MESNA; PLACEBO; SODIUM CHLORIDE; THIOL DERIVATIVE; EXPECTORANT AGENT;

ABDOMINAL PAIN; ANGIONEUROTIC EDEMA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEMOPTYSIS; HUMAN; LUNG FIBROSIS; LUNG FUNCTION TEST; PRIORITY JOURNAL; RASH; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CYSTIC FIBROSIS; DRUG EFFECT; INHALATIONAL DRUG ADMINISTRATION; LUNG DISEASE; META ANALYSIS; MUCOCILIARY CLEARANCE; NEBULIZER; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); COMPLICATION; DRUG EFFECTS; LUNG DISEASES;

ACETYLCYSTEINE; ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; AMBROXOL; CARBOCYSTEINE; CYSTIC FIBROSIS; EXPECTORANTS; GLUTATHIONE; HUMANS; LUNG DISEASES; MUCOCILIARY CLEARANCE; NEBULIZERS AND VAPORIZERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALINE SOLUTION, HYPERTONIC;

EID: 84891638906     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007168.pub3     Document Type: Review

References (56)

1. Bishop C, Hudson VM, Hilton SC, Wilde C. A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest 2005;127(1):308-17.
2. Caramia G, Gagliardini R, Ruffini E, Osimani P, Nobilini A. The management of cystic fibrosis with carbocysteine lysine salt: single-blind comparative study with ambroxol hydrochloride. The Journal of International Medical Research 1995;23:284-93.
3. Dauletbaev N, Fischer P, Aulbach B, Gross J, Kusche W, Thyroff-Friesinger U, et al. A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis. European Journal of Medical Research 2009;14(8):352-8.
4. Howatt WF, DeMuth GR. A double-blind study of the use of acetylcysteine in patients with cystic fibrosis. University of Michigan Medical Center Journal 1966;32(2):82-5.
5. Mitchell EA, Elliott RB. Controlled trial of oral N-acetylcysteine in cystic fibrosis. Australian Paediatric Journal 1982;18(1):40-2.
6. Ratjen F, Posselt HG, WönneR, Stöver B, Bender SWJW. A double-blind placebo controlled trial with ambroxol and N-Acetylcysteine for mucolytic treatment in cystic fibrosis [abstract]. Proceedings of the 9th International Cystic Fibrosis Congress; 1984 June 9-15; Brighton, England. 1984:3.04.
7. Ratjen F, Wonne R, Posselt HG, Stover B, Hofmann D, Bender SW. A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. European Journal of Pediatrics 1985;144(4):374-8.
8. Stafanger G, Garne S, Howitz P, Koch C. Effect of peroral N-acetylcysteine in patients with cystic fibrosis and primary cilia dyskinesia [abstract]. Proceedings of 14th Annual Meeting of the European Working Group for Cystic Fibrosis; 1986 Sept 1-2; Budapest, Hungary. 1986:129.
9. Stafanger G, Garne S, Howitz P, Morkassel E, Koch C. The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia. European Respiratory Journal 1988;1(2):161-7.
10. Stafanger G, Garne S, Howitz P, Koch C. The effect of oral Nacteylcysteine on lung function CF patients [abstract]. Excerpta Medica, Asia Pacific Congress Series 1988;74:R(c)29.
11. Stafanger G, Koch C. N-acetylcysteine in cystic fibrosis and Pseudomonas aeruginosa infection: clinical score, spirometry and ciliary motility. European Respiratory Journal 1989;2(3):234-7.
12. Weller P, Ingram D, Preece M, Matthew D. A controlled trial of intermittent aerosol therapy in patients with cystic fibrosis [abstract]. Proceedings of 9th Meeting European Working Group for Cystic Fibrosis; 1979 June 12-13; Noordwijkerhout, The Netherlands. 1979:58.
13. Weller PH, Ingram D, Preece MA, Matthew DJ. Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Thorax 1980;35(1):42-6.
14. App EM, Baran D, Dab I, Malfroot A, Coffiner M, Vanderbist F, et al. Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis. European Respiratory Journal 2002;19(2):294-302.
15. Casale A, Tosco A, Buonpensiero P, Di Pasqua A, De Santis S, De Gregorio F, et al. Inhaled GSH tolerability in patients with cystic fibrosis (CF) [abstract]. Journal of Cystic Fibrosis 2012;11 Suppl 1:S69 Abstract no: 51.
16. Cezeaux G Jr, Telford J, Harrison G, Keats AS. Bronchial lavage in cystic fibrosis. A comparison of agents. JAMA 1967;199(1):15-8.
17. Dasgupta B, King M. Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase. Pediatric Pulmonology 1996;22(3):161-6.
18. Dietzsch HJ, Gottschalk B, Heyne K, Leupoid W, Wunderlich P. Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride). Pediatrics 1975;55(1):96-100.
19. Gotz M, Kraemer R, Kerrebijn KF, Popow C. Oral acetylcysteine in cystic fibrosis. A co-operative study. European Journal of Respiratory Disease. Supplement 1980;111:122-6.
20. Griese M, Ramakers J, Krasselt A, Starosta V, van Koningsbruggen S, Fischer R, et al. Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2004;169(7):822-8.
21. Maayan C, Bar Yishay E, Yaacobi T, Marcus Y, Katznelson D, Yahav Y, et al. Immediate effect of various treatments on lung function in infants with cystic fibrosis. Respiration 1989;55(3):144-51.
22. Snyder AH, McPherson ME, Hunt JF, Johnson M, Stamler JS, Gaston B. Acute effects of aerosolized S-nitrosoglutathione in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2002;165(7):922-6.
23. Tecklin JS, Holsclaw DS. Bronchial drainage with aerosol medications in cystic fibrosis. Physical Therapy 1976;56(9):999-1003.
24. Tirouvanziam R, Conrad CK, Dunn CE, Davies ZA, Gernez Y, Aram B, et al. Phase 2 trial of high-dose oral N-Acetylcysteine as a systemic antioxidant and inhibitor of lung inflammation in CF [abstract]. Pediatric Pulmonology 2006;41(Suppl 29):295.
25. Griese M, Hector A, Kappler M, Ballmann M, Junge S, Rietschel E, et al. Inhaled glutathione in cystic fibrosis [abstract]. Journal of Cystic Fibrosis 2012;11 Suppl 1:S11, Abstract no: WS5.1.
26. Griese M, Kappler M, Eismann C, Ballmann M, Junge S, Rietschel E, et al. Inhalation treatment with glutathione in patients with cystic fibrosis: a randomised controlled trial. American Journal of Respiratory and Critical Care Medicine 2013:2013 April 30 [Epub ahead of print]. [CRS-ID: 5500100000011125]
27. Tirouvanziam R, Lymp J, Thompson V, Chatfield BA, Nicholls D, Clancy JP, et al. A multi-center, phase IIB, randomized, placebo-controlled, double-blind study of the effects of N-acetylcysteine (NAC) on redox changes and lung inflammation in cystic fibrosis patients [abstract]. Pediatric Pulmonology 2011;46 Suppl 34:280 Abstract no:196.
28. van Daele SG, De Prycker S, De Somville B, De Meester J, De Baets F. The effect of N-acetylcysteine on the visco-elasticity of sputum of cystic fibrosis patients [abstract]. Journal of Cystic Fibrosis 2011;10 Suppl 1:S18, Abstract no: 71.
29. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. American Review of Respiratory Disease 1991;144(5):1202-18.
30. Bonanomi L, Gazzaniga A. Toxicological, pharmacokinetic and metabolic studies on acetylcysteine. European Journal of Respiratory Disease 1980;111(Suppl):217-22.
31. Borregaard N, Jensen HS, Bjerrum OW. Prevention of tissue damage: inhibition of myeloperoxidase mediated inactivation of alpha 1-proteinase inhibitor by N-acetyl cysteine, glutathione and methionine. Agents Actions 1987;22(3-4):255-60.
32. Cystic Fibrosis Foundation. Annual Report. CFF Annual Report 2007.
33. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. American Journal of Epidemiology 1996;143(10):1007-17. [MEDLINE: 42]
34. Cotgreave IA, Eklund A, Larsson K, Moldeus PW. No penetration of orally administered N-acetylcysteine into bronchoalveolar lavage fluid. European Journal of Respiratory Disease 1987;70(2):73-7.
35. Curtin F, Altman DG, Elbourne D. Meta-analysis combining parallel and cross-over clinical trials.I: Continuous outcomes. Statistics in Medicine 2002;21:2131-44.
36. Davies JC, Cunningham S, Alton EW, Innes JA. Lung clearance index in CF: a sensitive marker of lung disease severity. Thorax 2008;63(2):96-97.
37. Davis P. Cystic Fibrosis since 1938. American Journal of Respiratory and Critical Care Medicine 2006;173(5):475-482.
38. Duijvestijn YC, Brand PL. Systematic review of N-acetylcysteine in cystic fibrosis. Acta Paediatrica 1999;88(1):38-41. [MEDLINE: 6]
39. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
40. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine 2006;354(3):229-40. [MEDLINE: 61]
41. Follmann D, Elliot P, Shuh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology 1992;45(7):769-73.
42. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. New England Journal of Medicine 1994;331(10):637-42. [MEDLINE: 62]
43. Henke MO, Renner A, Huber RM, Seeds MC, Rubin BK. MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions. American Journal of Respiratory Cell and Molecular Biology 2004;31(1):86-9.
44. Henke M, Ratjen F. Mucolytics in cystic fibrosis. Paediatric Respiratory Reviews 2007;8(1):24-9.
45. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
46. Higgins JPT, Altman DG, Sterne JAC behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
47. Jones AP, Wallis CE, Kearney CE. Recombinant human deoxyribonuclease for cystic fibrosis. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD001127]
48. Marriott C, Ingham S, Coffiner M, Fossion J, Maes P. Determination of the mode of action of a novel mucolytic agent Nacystelyn. European Respiratory Journal 1993;6(Suppl 17):438s.
49. Rahman I, Yang SR, Biswas SK. Current concepts of redox signaling in the lungs. Antioxid Redox Signal 2006;8(3-4):681-689.
50. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
51. Sheffner AL, Meyer FA. The in vitro reduction in viscosity of human tracheobronchial secretions by acetylcysteine. American Review of Respiratory Disease 1964;90:721-29.
52. Shimizu T, Shimizu S, Hattori R, Gabazza EC, Majima Y. In Vivo and In Vitro Effects of Macrolide Antibiotics on Mucus Secretion in Airway Epithelial Cells. American Journal of Respiratory and Critical Care Medicine 2003;168(5):581-7.
53. Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proceedings of the National Academy of Sciences of the United States of America 2006;103(12):4628-33.
54. Ventresca GP, Cicchetti V, Ferrari V. Acetylcysteine. In: Braga PC, Allegra L editor(s). Drugs in Bronchial Mucology. New York: Raven Press, 1989:77-102.
55. Wark PAB, McDonald V, Jones AP. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD001506.pub2]
56. Nash EF, Stephenson A, Ratjen F, Tullis E. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD007168.pub2]